Future research should examine whether ANXA3 alterations in MDD are state or trait markers, their response to pharmacological and non-pharmacological interventions, and their possible interaction with dysregulation of the calcium-PTH-vitamin D axis. The gene discussed is ANXA3; the disease is major depressive disorder.